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A B S T R A C T
In Finland (population 5 million) the organised Pap screening programme for preventing cervical cancer has been in
action already for 45 years. Women aged 30 to 64 are targeted (N 1.25 million) and the screening interval is five years.
The programme invites women seven times in a lifetime; the attendance rate per one screening invitational round is 73%.
The programme has affected markedly the cervical cancer rates in our country. During the decennia of its action there
has been about 80% decrease in the age-adjusted cervical cancer incidence and mortality rates. The current age-stand-
ardised incidence rate is 4 and mortality rate 1 per 100,000 woman-years. In the current article we describe the organisa-
tional aspects of the programme; and pay attention to renovation of the programme taken place during the last decade
when novel technological alternatives have been started to be used as the screening tests. By expanding the coverage and
compliance of screening we still expect to increase the impact of the programme. Same time, efforts are needed to avoid
overuse of services due to spontaneous screening, in order to decrease potential adverse effects and improve overall cost-
effectiveness. A large-scale public health policy trial on Human papillomavirus (HPV) screening is on-going. Cross-sec-
tional information available thus far suggests promising results. Follow-up of cancer rates after screening episodes are
still required to evaluate optimal screening policies (e.g., screening intervals by age groups, and starting and stopping
ages). We propose speeding up the use of modern technological alternatives in organised screening programmes.
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Introduction
In Finland (population 5 million) organised cervical
screening was introduced in the early 1960s; piloting
first within the area of three municipalities in 1963 and
extending within a few years time to most parts of the
country. From the early 1970s onwards, the registered
screening invitational coverage has been almost com-
plete within the centrally targeted screening ages.
During 1955–1964 the incidence of invasive cervical
cancer in Finland was at a level of 15 cases per 100,000
woman-years; age-adjusted to the world standard popu-
lation, with a slight increasing trend within the period.
Mortality from cervical cancer was around 7 cases per
100,000 woman-years, respectively. Subsequent to imple-
mentation of organised screening, there was a rapid de-
crease in the invasive cervical cancer incidence and mor-
tality rates. Currently the age-adjusted rates are 4 and 1
per 100,000 woman-years (Figure 1). Most of the reduc-
tion has occurred in the incidence of squamous cell carci-
nomas, whereas the incidence rate of cervical adenocar-
cinoma has been quite stable over the decades1,2.
Effectiveness of Conventional Screening
Screening effectiveness in Finland was demonstrated
first by a very large-scale cohort follow-up study among
women invited in the implementation phase of the pro-
gramme3,4. The study followed subsequent cervical can-
cer rates, based on about 425,000 invitations in 1963–
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1972. Most part of the women had been screened once
during the study period. The efficacy estimate among
screened was 80%. The attendance rate was 85% and the
effectiveness of the programme was estimated at 60%.
Among invited but not attended there was about 60% in-
crease in the subsequent cervical cancers in comparison
with the rates in the population before screening. It is
likely that thereafter the effectiveness of the programme
has increased, as more testing rounds have become avail-
able. However, there are mainly a number of ecologi-
cal-level trend studies performed in the later years in our
country (see IARC, 20054, for a recent synthesis on
these). According to a cohort follow-up study among a
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Fig. 1. Cervical cancer incidence and mortality rates in Finland






































































Fig. 2. Observed (Finnish Cancer Registry, 2007) and predicted
(from Hristova & Hakama, 19976) mortality rates from cervical
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sample of women with a negative cytological result in the
programme, the absolute rate of cervical cancer after
screening negative is about 5 cases per 100,000 woman-
years5.
It is estimated based on the trends that each year al-
most 300 deaths are prevented due to Pap-screening;
these deaths would have occurred at a broad set of ages
from rather young (30 or 35 years) up to very old (more
than 85 years) women (Figure 2)6. In the oldest age
groups the incidence and mortality rates from cervical
cancer are still expected to decrease due to ageing of fe-
male population screened previously in their life. There
are still some 60 deaths per year, and the number of inci-
dence cases is 160.
The incidence of cervical cancer has somewhat in-
creased during the last decade in ages 25–39 (Figure 3)
even though the number of cases in this age group is still
small, below 30 cases annually (Figure 4). There are al-
most no deaths from this cancer type in ages below 50
years and the death rate among young women has not in-
creased.
Growing Concerns on Opportunistic
Screening
In the early days, opportunistic screening was not
available in large-scale. Later on, use of such services has
increased. There are no data to study the trends in the
use of opportunistic screening. According to information
from an annual population survey as available from late
1990s7, any Pap smears (the estimate including also the
opportunistic and diagnostic smears in addition to the
programme smears) have been taken during a five-year
period roughly for 93% of the women at target ages of the
programme. The estimated coverage of any smears life-
time is 98%, respectively8,9. Trend studies4 and a popula-
tion-based case-control study using questionnaire-based
self-reported information on the screening history (ever
vs. never screened)8 have suggested that the overall ef-
fect in decreasing cervical cancer incidence with sponta-
neous smears is up to 40%. In the latter study the effect
among women participating in organised screening was
about two-fold compared to those who had never partici-
pated (but given only spontaneous smears); spontaneous
screening showed no additional impact among those sub-
jected to organised screening.
One problem in the national screening policy is that
there are apparently wide testing practices outside scree-
ning, also in rather young women – where almost all of
the pre-cancerous lesions would regress naturally (see
IARC, 20054 for estimates of regression probabilities).
Figure 4 illustrates the numbers of CIN3/CIS incidence
and treatments as available from cancer registry files:
about 60% of these are diagnosed already in age before
screening. More evaluation research, including also re-
search on the potential adverse effects, on any screening
is needed. There are yet no register-based data available
on the spontaneous screening; such data is required in
order to evaluate that activity and reduce the unneces-
sary actions. Recently, efforts have been started to in-
clude any smears in register-based evaluations.
Organisation of Cervical Cancer Screening
The screening activities have become an integral part
of the health care system. Women in ages 30 to 60 years
are invited with help of population registry, using a
five-year interval when normal screening results. The
two older age groups (55, 60) were added to the pro-
gramme only in 1990s. There are nowadays thus seven
invitations lifetime. Some municipalities invite also wo-
men in ages 25 and/or 65; women at a younger age than








































































Fig. 4. Cumulative number of cases of severe dysplasia or carci-
noma in situ (CIN3/CIS), cervical cancer incidence,0 and deaths
from cervical cancer in Finland, annual averages in 1998 over
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25 are not encouraged to be screened (http://www.kay
pahoito.fi/). In the organised programme the present cov-
erage of invitations is 95% of the target age (http://www.
cancerregistry.fi/statistics). In one calendar year, there is
about 250,000 invitations in the programme. The atten-
dance rate is more than 70%.
Even though the attendance rate is satisfactory, close
to 80%, in the older targeted ages, one main problem in
the programme is the fact that among young targeted
ages, particularly, in ages 25 to 35, the rate is very low,
only slightly above 60%. This has lead to the situation
that hardly half of the targeted population participates
in those ages (Figure 5).
Attending organised screening for women is free of
charge. Sample taking is done by trained nurses or mid-
wives in the local primary health care centres or clinics.
The sample quality is under continuous control done by
the cytology laboratories, based on individual coding for
sample-takers for a potential personal feed-back. The
samples taken are VCE smears; i.e., samples from poste-
rior vaginal fornix, cervix, and from endocervical canal
are taken separately, using Ayre’s spatula and endo-
cervical brush, and are placed on the same slide. The
samples are stained with modified Papanicolaou stain-
ing. The samples are screened by cytotechnicians, and
the cytologist checks every abnormal smear and a pro-
portion of normal smears. More recently, also the Human
papillomavirus (HPV)-DNA samples are taken in con-
tracted municipalities (see below).
There are some 15 cytology laboratories contracted by
the municipalities to the programme. Confirmation and
treatment is integrated into the normal health care rou-
tines. Treatment is provided for women with relatively
mild lesions (CIN1) or with a more severe finding. All the
data on the confirmation are included on the personal
screening cards kept for every woman in the cytology lab-
oratory; they are registered and the compliance and ade-
quacy of treatment followed by the cytology laboratory
and also by the mass screening registry.
The average referral rate is constantly about 1%, and
the detection rate for an CIN+ (cervical intraepithelial
neoplasia, or a worse histologically confirmed finding)
about 0.3–0.5%. In addition, about 6% of the screened
women get a re-invitation within a shorter interval, usu-
ally one year, based on borderline cytology (Table 1).
There is still some variation in the detection rates and
performance parameters which appear not to reflect di-
rectly the effectiveness aspects but, rather, some varia-
tion in the local cost-effectiveness10.
Data collection infrastructures
Screening laboratories are responsible for recording
screening visit and confirmation and treatment informa-
tion within the programme. The invitational and screen-
ing data of the programme, including cytological and
histological screening findings, are filed centrally at the
Mass Screening Registry that it a subunit within the na-
tional Finnish Cancer Registry. This makes an efficient
tool for evaluation and monitoring of the programme.
The Finnish Cancer Registry provides complete data on
cancer incidence and mortality, arranged individually
with the help of the unique personal identifier. The mor-
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TABLE 1
CERVICAL CANCER SCREENING PROGRAMME IN FINLAND IN 2004: THE NUMBER AND PERCENTAGE DISTRIBUTION OF
SCREENING TESTS IN THE ORGANISED SCREENING PROGRAMME, BY SCREENING TEST RESULTS, REFERRALS AND FINAL
HISTOLOGICAL DIAGNOSIS (MASS SCREENING REGISTRY, 2007, PRELIMINARY INFORMATION BASED ON DATA FROM 437





Cervix cancer CIN3/CIS CIN2 CIN1 Other or normal
N N % N % N % N % N % N %
Pap-test 170205 1290 0.8 18 0.01 178 0.1 192 0.1 175 0.1 727 0.4
I 158894 – – – – – – – – – – – –
II 10022 132 0.1 1 0.0 4 0.0 6 0.0 10 0.01 111 0.07
III–V 1161 1158 0.7 17 0.01 174 0.1 186 0.1 165 0.1 616 0.4
Inadequate 128 – – – – – – – – – – – –
HPV-test 14585 186 1.3 4 0.03 14 0.1 48 0.3 32 0.2 88 0.6
Negative 13433 7 0.05 – – 1 0.01 – – 1 0.01 5 0.03
Positive 1152 179 1.2 4 0.03 13 0.09 48 0.3 31 0.2 83 0.6
All 184790 1476 0.8 22 0.01 192 0.1 240 0.1 207 0.1 815 0.4
CIN – Cervical Intra-epithelial Neoplasia, CIS – Carcinoma in situ, Pap – Papanicolaou, HPV – Human papillomavirus, – magnitude
nil, women with Papanicolaou group I or II or HPV test negative are not referred for further examinations unless repeated cytology or
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tality records are obtained from the files of the Cause-
of-Death Registry at the Statistics Finland. The cancer
registry notifies also carcinoma in situ cases of the cervix
uteri (CIS, including both squamous and adenocarcino-
ma in situ cases), as well as cases of severe intraepithelial
neoplasia (dysplasia gravis, or CIN3 not specified in more
detail).
Quality assurance
In the normal screening practice of the organised
programme there is a number of quality control activi-
ties, such as control of sample quality that takes place
mainly within the cytological laboratories within the
programme9; and re-reading, consultation and training
meetings; even though there have been no systematic
publications on their results. Important for developing
the screening specificity criteria, there are, normally,
weekly sessions between cytology and pathology units/
laboratories. Since 1999 a systematic re-reading pro-
gramme of potentially false negative smears have been in
action; including re-reading of these smears together
with control slides both in a reference laboratory and in
the original screening laboratory. This material is based
on linkages between the screening and cancer registry
files.
Novel Screening Methods
The main aim of the evaluation of alternative screen-
ing techniques is to assess screening effectiveness, i.e.,
comparing incidence of subsequent cervical cancers as
the outcome and screen-detected pre-cancers as surro-
gates. Also performance e.g. in form of screen-detected
findings will be monitored and compared. It is important
to verify that, if the treatment rates would increase, it re-
flects, respectively, to better efficacy and effectiveness.
Modifications on the screening policy need also to be con-
sidered, e.g. the need of lifetime number of tests in the
programme. For the time being, approximately 860,000
women have been allocated to automation-assisted cyto-
logy, HPV DNA testing, or to conventional cytology with-
in the organised screening programme11,12,13. In the HPV-
-DNA screening arm, run within a restricted area, the
plan is to invite about 100,000 women in 2003–2008. In
numerical terms, almost 10% of the whole national tar-
get population will be subjected to HPV screening. Fol-
low-up results on subsequent cervical cancers will become
available during 2007– 2015.
First reports on screening detection rates are avai-
lable12,13. Screening detection rates as well as specificity
estimates in automation-assisted screening are very sim-
ilar to conventional screening. Based on early results
from HPV screening, the detection rate of mild pre-can-
cerous lesions was in excess in the HPV screening pro-
tocol12; see also Table 1 on the routine statistics on 2004.
CIN3+ detection rates were about the same as in con-
ventional screening. There is a cytological triage protocol
after a positive primary HPV test. Noteworthy, when
considering the referral to colposcopy, based on the cytol-
ogy triage, the cross-sectional specificity and positive
predictive value estimates were closely resembling those
of the conventional screening.
Discussion
Historically, the overall incidence of invasive cervical
cancer, as well as that of in situ carcinoma of the cervix
uteri, has drastically decreased in those ages subject to
organised screening activities. Organised screening is ef-
fective. There is no similar decrease in the CIN detection
frequencies, however. On the contrary, the detection ra-
tes of CIN grades 2 and 3 have even slightly increased2,
indicating that the biologic background risk has been
likely increased. Also invasive cervical cancer incidence
has increased in ages 25–39 years, even though based on
a small number of cases registered annually. This still
warrants improvements in the rather poor attendance
rate in the programme in the above young targeted ages.
Interventions testing written reminder or, preferably, re-
minding by phone, are required14. Self-sampling could
also be tested in order to check whether one can increase
compliance meaningfully.
On the other hand, based on the finding that a very
large proportion of registered CIN3/CIS cases have been
detected and treated outside the organised programme,
e.g. in opportunistic screening, in parallel with improv-
ing the population-based coverage and access to the ser-
vices, also decrease and stopping of unnecessary actions
should take place.
Concluding Remarks
Following from the 45-year period of its action the
cervical cancer screening programme in Finland has con-
tributed to a large decrease in cervical cancer incidence
and mortality rates. The purpose of cervical cancer scree-
ning is to prevent mortality and incidence from the dis-
ease. One can conclude that organised screening is effec-
tive in combating cervical cancers. With introducing mo-
dern screening technologies and more systematic quality
control activities in the programme, and moderately ex-
panding the coverage and as well as compliance – partic-
ularly, at the young target ages of the programme – we
still aim to increase the effectiveness of the programme.
Alternative methods in screening, such as automation-
assisted screening and HPV testing, have shown promis-
ing cross-sectional findings. We propose speeding up the
use of modern technological alternatives in organised
screening programmes. Follow-up information of cervical
cancers in still required, to acquire evidence for possible
modifications on the screening policies.
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PROGRAM PROBIRA RAKA VRATA MATERNICE U FINSKOJ S PRIMJEROM
UVO\ENJA ALTERNATIVNIH METODA PROBIRA
S A @ E T A K
U Finskoj (5 milijuna stanovnika) je organizirani program Papa-testiranja u prevenciji raka vrata maternice u upo-
trebi ve} 45 godina. Testiranje obuhva}a `ene u dobi od 30 do 64 godine (1,25 milijuna), a period izme|u dva testiranja
je pet godina. Prema programu, `ene se poziva sedam puta tijekom `ivota; odaziv jednoj rundi poziva na testiranje je
73%. Ovaj program je zna~ajno utjecao na stopu pojave raka vrata maternice u na{oj zemlji. Tijekom desetlje}a njegove
primjene zabilje`en je pad od oko 80% u dobno-standardiziranim stopama pojavnosti i smrtnosti od raka vrata ma-
ternice. Trenutna stopa pojavnosti, obzirom na dob je 4, a stopa smrtnosti 1 na 100.000 `ena godi{nje. U ovom ~lanku
opisujemo organizacijske zna~ajke programa; sva pa`nja je usmjerena na obnovu programa tijekom zadnjeg desetlje}a s
novim, alternativnim metodama koje su se po~ele koristiti u sklopu testova probira. Pove}anjem pokrivenosti i su-
glasnosti s programom, o~ekujemo pove}anje utjecaja programa. Istovremeno, potreban je napor kako bi se izbjegla
pretjerana upotreba slu`bi zahvaljuju}i spontanom probiru, sa svrhom smanjenja mogu}ih {tetnih u~inaka te sma-
njenja tro{kova. Trenutno se poku{ava uvesti pokrivanje tro{kova testiranja na HPV kroz zdravstveno osiguranje.
O~ekujemo povoljne rezultate. Pra}enje stope raka nakon testova probira je potrebno i dalje kako bi se procijenila
najbolja strategija probira (vremenski razmaci izme|u testiranja po dobnim skupinama te po~etna i zavr{na dob). Pred-
la`emo br`e uvo|enje novih, modernih metoda u organiziranim programima probira.
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